Symbiosis to move to SDI Boston incubator office
With the move the company plans to increase its foothold in the US with the help of existing European and US pharmaceutical regulations. SDI America president Danny Cusick
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Certolizumab pegol, a PEGylated anti-TNF (Tumour Necrosis Factor alpha), is indicated to treat moderate to severe active rheumatoid arthritis (RA), in combination with methotrexate, in adult patients when